AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30623736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy (20 mL sterile cold saline solution at 2.5 °C for 5 min)
Number of subjects: 60
Study 30623736 — intervention group
Group type: COMPARATOR
Intervention: Control group (sterile saline solution at room temperature)
Number of subjects: 60
Study 27323324 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) plus physical therapy
Number of subjects: 30
Study 27323324 — intervention group
Group type: COMPARATOR
Intervention: Sham shock wave plus physical therapy
Number of subjects: 30
Study 25444236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech AAC systems (special smiles for special children material)
Number of subjects: 60
Study 25444236 — intervention group
Group type: COMPARATOR
Intervention: Low-tech AAC systems
Number of subjects: 60
Study 25444236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech AAC systems
Number of subjects: 60
Study 25444236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Low-tech and High-tech AAC systems)
Number of subjects: 60
Study 23421363 — intervention group
Group type: EXPERIMENTAL
Intervention: Texas Implementation of Medication Algorithm (TIMA) for Bipolar Disorder
Number of subjects: 0
Study 23421363 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 22117977 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified submuscular transposition with Z‐lengthening of the pronator teres origin
Number of subjects: 278
Study 22117977 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous transposition
Number of subjects: 278
Study 19863304 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 30
Study 17680957 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced RBC transfusions (LR)
Number of subjects: 1085
Study 17680957 — intervention group
Group type: COMPARATOR
Intervention: Standard buffy-coat-depleted RBC transfusions (BCD)
Number of subjects: 1085
Study 15299099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (HSC infusion)
Number of subjects: 24
Study 15299099 — intervention group
Group type: COMPARATOR
Intervention: Group B (Control)
Number of subjects: 24
Study 11023568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy using a 5.3 mm fiberscope
Number of subjects: 160
Study 11023568 — intervention group
Group type: COMPARATOR
Intervention: Transoral endoscopy using a standard upper endoscope
Number of subjects: 160
Study 9096446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 76
Study 9096446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) continued for another 12 months
Number of subjects: 76
Study 9096446 — intervention group
Group type: COMPARATOR
Intervention: Conventional heparin
Number of subjects: 76
Study 8211369 — intervention group
Group type: EXPERIMENTAL
Intervention: Static lumbar traction
Number of subjects: 100
Study 8211369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent lumbar traction
Number of subjects: 100
Study 3698519 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal nerve blockade
Number of subjects: 9
Study 3698519 — intervention group
Group type: EXPERIMENTAL
Intervention: Local beta-receptor blockade
Number of subjects: 9
Study 3698519 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal cardiac performance)
Number of subjects: 9
Study 3698519 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients
Number of subjects: 9
Study 3698519 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in local venous transmural pressure
Number of subjects: 9
Study 3698519 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in forearm perfusion pressure
Number of subjects: 9
Study 3698519 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FSVR and plasma concentrations of noradrenaline and adrenaline
Number of subjects: 9
Study 4576562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study 4576562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 0
Study 4576562 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide and nandrolone decanoate
Number of subjects: 0
Study 31688865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0
Study 31688865 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 30172964 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated leadership
Number of subjects: 408
Study 30172964 — intervention group
Group type: COMPARATOR
Intervention: Emergent leadership
Number of subjects: 408
Study 30172964 — intervention group
Group type: COMPARATOR
Intervention: Smaller teams (3 rescuers)
Number of subjects: 408
Study 30172964 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger teams (6 rescuers)
Number of subjects: 408
Study 27129426 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine (HD TIV)
Number of subjects: 85
Study 27129426 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose trivalent inactivated influenza vaccine (SD TIV)
Number of subjects: 85
Study 25188774 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg) as an adjuvant to levobupivacaine (Chirocaine)
Number of subjects: 120
Study 25188774 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (Chirocaine) alone
Number of subjects: 120
Study 22024920 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160 μg/4.5 μg ten inhalations daily for 3 days via Turbuhaler®
Number of subjects: 25
Study 22024920 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.4 mg ten inhalations daily for 3 days via Turbuhaler®
Number of subjects: 25
Study 20228284 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconscious processing (performing an unrelated distracter task)
Number of subjects: 0
Study 20228284 — intervention group
Group type: COMPARATOR
Intervention: Conscious processing (consciously thinking about the information)
Number of subjects: 0
Study 17666035 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study 15682362 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible regional wall motion abnormalities (RWMAs) identified in 102 patients
Number of subjects: 303
Study 15682362 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststress RWMAs
Number of subjects: 303
Study 15682362 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of ischemia
Number of subjects: 303
Study 15682362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of prescan and perfusion data with poststress RWMAs
Number of subjects: 303
Study 12088920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) replacement
Number of subjects: 41
Study 10205235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (up to 9 microg/kg body weight per minute)
Number of subjects: 13
Study 7542966 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual laser ablation of the prostate using the Urolase right-angle fiber
Number of subjects: 0
Study 7542966 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostatectomy
Number of subjects: 0
Study 2222941 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 12
Study 2222941 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study 361059 — intervention group
Group type: EXPERIMENTAL
Intervention: diflucortolone valerate 0.3% ointment
Number of subjects: 354
Study 361059 — intervention group
Group type: COMPARATOR
Intervention: clobetasol propionate 0.05% ointment
Number of subjects: 354
Study 31917692 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in STEMI patients with CAA
Number of subjects: 8131
Study 31917692 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in NSTEMI patients with CAA
Number of subjects: 8131
Study 31917692 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PCI rate in patients with CAA
Number of subjects: 8131
Study 31917692 — intervention group
Group type: COMPARATOR
Intervention: Revascularization trends in AMI patients with CAA
Number of subjects: 8131
Study 31530081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 100
Study 31530081 — intervention group
Group type: COMPARATOR
Intervention: Instrumented posterolateral fusion (PLF)
Number of subjects: 100
Study 28799710 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous N95 respirator use
Number of subjects: 3591
Study 28799710 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted N95 respirator use
Number of subjects: 3591
Study 28799710 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical mask use
Number of subjects: 3591
Study 28799710 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 3591
Study 25811263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR)
Number of subjects: 0
Study 25811263 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 0
Study 23830094 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 mcg
Number of subjects: 1532
Study 20829308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine medication
Number of subjects: 0
Study 20829308 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 0
Study 19480657 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg p.o.)
Number of subjects: 12
Study 19480657 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg i.v.)
Number of subjects: 12
Study 17666197 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0
Study 17666197 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 17666197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and ramipril
Number of subjects: 0
Study 17666197 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 0
Study 17666197 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study 14574621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fighting Spirit (Mental Adjustment to Cancer, MAC) in the Graz sample
Number of subjects: 424
Study 14574621 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Family Support (PFS) in the Jerusalem sample
Number of subjects: 424
Study 11224753 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine) at 0.1 mmol/kg
Number of subjects: 205
Study 11224753 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine) at 0.05 mmol/kg
Number of subjects: 205
Study 11224753 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine) cumulative doses
Number of subjects: 205
Study 11224753 — intervention group
Group type: COMPARATOR
Intervention: Omniscan (gadodiamide) at 0.1 mmol/kg
Number of subjects: 205
Study 11224753 — intervention group
Group type: COMPARATOR
Intervention: Omniscan (gadodiamide) at 0.3 mmol/kg
Number of subjects: 205
Study 15102402 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 400 ms
Number of subjects: 12
Study 15102402 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 200 ms
Number of subjects: 12
Study 8284093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment at day 10 (n = 14)
Number of subjects: 27
Study 8284093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no respiratory disease or recovered from respiratory distress syndrome, n = 10)
Number of subjects: 27
Study 8284093 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone treatment at day 16 (n = 13)
Number of subjects: 27
Study 2892881 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 6570
Study 2892881 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 6570
Study 29283590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing, Graded Activity, and Cognitive Behavioral Therapy
Number of subjects: 0
Study 29283590 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28122622 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 1677
Study 28122622 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 1677
Study 28122622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (SMS reminders)
Number of subjects: 1677
Study 25453534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide therapy
Number of subjects: 811
Study 25453534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 811
Study 23290142 — intervention group
Group type: EXPERIMENTAL
Intervention: Seromuscular tunnel anastomosis
Number of subjects: 62
Study 23290142 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-cuff nipple reimplantation
Number of subjects: 62
Study 21640782 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10mg
Number of subjects: 12
Study 21640782 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20mg
Number of subjects: 12
Study 21640782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18586762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous C.E.R.A. administered once every 2 weeks (Q2W)
Number of subjects: 313
Study 18586762 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (DA) administered once weekly (QW)
Number of subjects: 313
Study 17139037 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioural therapy
Number of subjects: 113
Study 17139037 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 113
Study 12919163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 10 mg with breakfast and 5 mg with lunch (Schedule 1)
Number of subjects: 26
Study 12919163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone with the addition of 5 mg with the evening meal (Schedule 2)
Number of subjects: 26
Study 12919163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/15 kg body weight given per day with breakfast only (Schedule 3)
Number of subjects: 26
Study 12919163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Schedule 3)
Number of subjects: 26
Study 12919163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone schedules (1 and 2)
Number of subjects: 26
Study 12919163 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study 12919163 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatment schedules
Number of subjects: 26
Study 12919163 — intervention group
Group type: EXPERIMENTAL
Intervention: All three replacement schedules
Number of subjects: 26
Study 10488714 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI) assessment using 29 fluorescence-labeled microsatellite markers
Number of subjects: 38
Study 10488714 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity assessment in 29 markers
Number of subjects: 38
Study 10488714 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of replication errors in coding regions of specific genes
Number of subjects: 38
Study 8909439 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide T 6 mg/day
Number of subjects: 81
Study 8909439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 1857947 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine solution
Number of subjects: 7
Study 1857947 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (WHO) solution
Number of subjects: 7
Study 1857947 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycose solution
Number of subjects: 7
Study 1857947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-flour solution
Number of subjects: 7
Study 6354523 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dihydrotestosterone (DHT) 125 mg twice daily
Number of subjects: 43
Study 6354523 — intervention group
Group type: COMPARATOR
Intervention: DHT therapy (group B)
Number of subjects: 43
Study 6354523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 43
Study 6354523 — intervention group
Group type: EXPERIMENTAL
Intervention: DHT treatment (group A)
Number of subjects: 43
Study 30873752 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention (OP) - 14-session phone-based
Number of subjects: 421
Study 30873752 — intervention group
Group type: COMPARATOR
Intervention: Safety and injury prevention contact control (CC)
Number of subjects: 421
Study 29149143 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 20 mL per side of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg)
Number of subjects: 60
Study 29149143 — intervention group
Group type: COMPARATOR
Intervention: TAP block with 20 mL per side of 0.25% bupivacaine
Number of subjects: 60
Study 26141307 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT intervention (Sharing Patient's Illness Representations to Increase Trust)
Number of subjects: 420
Study 26141307 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 420
Study 23601452 — intervention group
Group type: EXPERIMENTAL
Intervention: METABO
Number of subjects: 70
Study 23601452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21108699 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2a and ribavirin (RBV)
Number of subjects: 3070
Study 21108699 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2b and ribavirin (RBV)
Number of subjects: 3070
Study 19845267 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoanal ultrasonography
Number of subjects: 214
Study 19845267 — intervention group
Group type: COMPARATOR
Intervention: No preoperative endoanal ultrasonography
Number of subjects: 214
Study 16706948 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Sea (topical jellyfish sting inhibitor)
Number of subjects: 82
Study 16706948 — intervention group
Group type: COMPARATOR
Intervention: Coppertone (placebo control)
Number of subjects: 82
Study 15006886 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 230
Study 15006886 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 230
Study 11896407 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV (lower-titer formulation: 4 x 10(4) pfu/dose)
Number of subjects: 0
Study 11896407 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV
Number of subjects: 0
Study 11896407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9539588 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 82
Study 9539588 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 82
Study 8697047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 1441
Study 8697047 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1441
Study 1699861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon therapy
Number of subjects: 30
Study 380609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (250 mg i.v. infusion)
Number of subjects: 5
Study 380609 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine (250 mg i.v. infusion)
Number of subjects: 5
Study 6303793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CAMP-L: cyclophosphamide, doxorubicin, methotrexate, procarbazine, leucovorin)
Number of subjects: 56
Study 6303793 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (methotrexate/leucovorin followed by cyclophosphamide/doxorubicin at progression)
Number of subjects: 56
Study 6303793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 56
Study 6303793 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial response
Number of subjects: 56
Study 6303793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable disease
Number of subjects: 56
Study 6303793 — intervention group
Group type: EXPERIMENTAL
Intervention: No response
Number of subjects: 56
Study 29224638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge therapy with dalteparin 100 IU/kg twice daily
Number of subjects: 1813
Study 29224638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1813
Study 29224638 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative aspirin use
Number of subjects: 1813
Study 29224638 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedure international normalized ratio >3.0
Number of subjects: 1813
Study 29224638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-bleeding risk procedures
Number of subjects: 1813
Study 29224638 — intervention group
Group type: EXPERIMENTAL
Intervention: History of renal disease
Number of subjects: 1813
Study 29224638 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-dependent risk in the first 10 days postprocedure
Number of subjects: 1813
Study 27838534 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Promoting Lifestyle (HPL) education
Number of subjects: 64
Study 27838534 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 25432270 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized performance feedback (n=46)
Number of subjects: 133
Study 25432270 — intervention group
Group type: COMPARATOR
Intervention: Practice-only condition (weekly writing practice; n=39)
Number of subjects: 133
Study 25432270 — intervention group
Group type: COMPARATOR
Intervention: Instructional control condition (n=48)
Number of subjects: 133
Study 22428764 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (Pinot Noir)
Number of subjects: 120
Study 22428764 — intervention group
Group type: COMPARATOR
Intervention: White wine (Chardonnay-Pinot)
Number of subjects: 120